CNBX Pharmaceuticals (CNBX) Stock Price & Analysis
CNBX Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- $0.01 - $0.02
- Previous Close
- $0.01
- Volume
- 5.81M
- Average Volume (3M)
- 73.87K
- Market Cap
- $321.15K
- Enterprise Value
- $76.72B
- Total Cash (Recent Filing)
- $9,487
- Total Debt (Recent Filing)
- $120.00K
- Price to Earnings (P/E)
- ―
- Beta
- 17.35
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
CNBX Pharmaceuticals News
CNBX FAQ
What was CNBX Pharmaceuticals’s price range in the past 12 months?
What is CNBX Pharmaceuticals’s market cap?
When is CNBX Pharmaceuticals’s upcoming earnings report date?
Is CNBX Pharmaceuticals overvalued?
Does CNBX Pharmaceuticals pay dividends?
What is CNBX Pharmaceuticals’s EPS estimate?
How many shares outstanding does CNBX Pharmaceuticals have?
Which hedge fund is a major shareholder of CNBX Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eyal Barad
- Employees
- 1
- Website
- www.cnbxpharma.com
- Address
- #3 Bethesda Metro Center, Bethesda, MD, 20814, US

